Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 15/20 | 0.67 |
| ▸ | GABRB3 | P28472 | 15/20 | 0.67 |
| ▸ | GABRA5 | P31644 | 15/20 | 0.67 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.64 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.64 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18329263 | 1.00 | GABRG2 (0.67) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL18412358 | 0.91 | GABRG2 (0.66) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL18329247 | 0.90 | GABRG2 (0.53) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL29618007 | 0.90 | GABRG2 (0.53) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL29769270 | 0.90 | GABRG2 (0.67) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL16840272 | 0.89 | GABRG2 (0.80) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL20755587 | 0.89 | GABRG2 (0.61) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL29618011 | 0.89 | GABRG2 (0.53) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL18329267 | 0.88 | GABRG2 (0.61) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL29769257 | 0.88 | GABRG2 (0.68) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| US-11505555-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220274996-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2022-09-01 | — | — | US | disclosed |
| US-11414425-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRG2 24/4885GABRB3 15/4885GABRA5 2/4885 |
| US-11505555-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRG2 20/4885GABRB3 15/4885GABRA5 2/4885 |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRG2 22/4885GABRB3 16/4885GABRA5 2/4885 |
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | GABRG2 14/4885GABRB3 11/4885GABRA5 1/4885 |
| US-11414425-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRA1 | GABRG2 14/4885GABRB3 11/4885GABRA5 1/4885 |
| US-20220274996-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRG2 24/4885GABRB3 15/4885GABRA5 2/4885 |
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRA1 | GABRG2 14/4885GABRB3 11/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.